Health & Fitness
Wed, April 6, 2011Tue, April 5, 2011Mon, April 4, 2011Sun, April 3, 2011Sat, April 2, 2011Fri, April 1, 2011Thu, March 31, 2011Wed, March 30, 2011Tue, March 29, 2011Mon, March 28, 2011Sun, March 27, 2011Fri, March 25, 2011Thu, March 24, 2011Wed, March 23, 2011Tue, March 22, 2011Mon, March 21, 2011Sun, March 20, 2011Fri, March 18, 2011Thu, March 17, 2011Wed, March 16, 2011Positrona?s PosiRx System Readies for Commercial Deployment
Published in Health and Fitness on Monday, March 28th 2011 at 7:10 GMT by Market Wire
INDIANAPOLIS--([ BUSINESS WIRE ])--Positron Corporation (OTCBB: POSC) is pleased to announce that its PosiRx system has met critical test standards and guidelines necessary to move on to the commercial deployment stage of its development. Following significant internal testing, Positron sought the expertise and resources of an independent 3rd party for further evaluation of its system, engaging the services the New Mexico Center for Isotopes in Medicine at the University of New Mexico (UNM) to assist in developing tests and validation protocols for the PosiRx system.
Positron installed a PosiRx Beta system at UNM in February 2011 and recently, the system successfully completed testing of key criteria required for validation. Procedures of the PosiRx system were performed with sestamibi drawn from Covidien Ultra-TechneKow® DTE (Technetium Tc 99m) generators at the Universitya™s facilities.
The PosiRx system is an automated radiopharmaceutical system that performs the complex series of steps involved in the preparation and manufacturing of unit dose SPECT pharmaceuticals such as technetium 99/sestamibi. The system was designed to meet stringent standards for compounding that include; air quality (ISO class 5), ensuring proper radiochemical purity of kits, adherence to ALARA principles for shielding the process within the equipment, product sterility, volume and activity dose accuracy through calibration, molybdenum breakthrough testing of generator elutions and basic usability.
PosiRx is the next generation of technology based on further development of the Nuclear Pharm-Assist line of pharmacy PET dispensing machines for the automation of FDG unit dose deliver. The PosiRx system provides a solution that is tailored to a wide set of users in the SPECT market that includes pharmacies, hospitals and private practices that perform diagnostic imaging. Positron will continue the development of the PosiRx system platform that will enhance its value and user base through improved software integration, and additional configurations that will handle many other radiopharmaceuticals.
About Positron: Positron is a molecular imaging company focused on Nuclear Cardiology. Positron Corporation, a pioneer in molecular imaging for more than 25 years provides unique solutions for the nuclear medicine community through the production and distribution of proprietary molecular imaging systems and radiopharmaceutical products. More information about Positron is available at [ www.positron.com ].
About CSIR Group: Headquartered in New York City, the CSIR Group offers public and soon-to-be public companies a complete array of investor relations services, working primarily with emerging market and market-leading small companies. With over thirty years of experience and wealth of contacts in the investment community, the CSIR Group provides clients with world-class investor relations advice, [ www.csirgroup.com ].
Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance and may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Positron assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.
For further information please contact Positron Corporation at (317)576-0183.
